该杂志的目的是提供专家对心血管医学当前进展的及时观点。我们还寻求提供评论，突出从大量可用的心血管文献中选出的最近发表的最重要的论文。我们通过任命跨学科主要学科领域的关键权威来实现这一目标。栏目编辑选择由主要专家审查的主题，这些专家强调最近的发展并突出过去一年发表的重要论文。由国际多元化成员组成的编辑委员会建议其国家/地区特别感兴趣的主题，并确保主题是最新的并包括新兴研究。我们还提供该领域知名人士的评论。

Current Cardiology Reports aims to provide timely expert opinions on the latest advancements in cardiovascular medicine. We also seek to offer reviews that highlight the most significant papers recently published from the vast array of cardiovascular literature. This is achieved by appointing key authorities from interdisciplinary fields as section editors, who select topics reviewed by leading experts, emphasizing recent developments and highlighting important papers published in the past year. An editorial board composed of internationally diverse members suggests topics of particular interest to their respective countries/regions, ensuring that the subjects are current and include emerging research. Additionally, we provide commentary from prominent figures in the field.

《Current Cardiology Reports》旨在提供心血管医学领域最新进展的专家观点。我们还希望提供评论，突出从大量心血管文献中选出的最近发表的重要论文。为实现这一目标，我们任命跨学科领域的关键权威作为栏目编辑，选择由主要专家审查的主题，强调最近的发展，并突出过去一年发表的重要论文。由国际多元化成员组成的编辑委员会建议与其国家/地区特别相关的主题，确保这些主题是最新的，并涵盖新兴研究。此外，我们还提供该领域知名人士的评论。

Current Cardiology Reports

Abstract Purpose of Review The article aims to investigate the complex relationship between cancer and cardiovascular disease (CVD), with a focus on the effects of cancer treatment on cardiac health. Recent Findings Advances in cancer treatment have improved long-term survival rates, but CVD has emerged as a leading cause of morbidity and mortality in cancer patients. The interplay between cancer itself, treatment methods, homeostatic changes, and lifestyle modifications contributes to this comorbidity. Recent research in the field of cardio-oncology has revealed common genetic mutations, risk factors, and metabolic features associated with the co-occurrence of cancer and CVD. Summary This article provides a comprehensive review of the latest research in cardio-oncology, including common genetic mutations, risk factors, and metabolic features, and explores the interactions between cancer treatment and CVD drugs, proposing novel approaches for the management of cancer and CVD.

Yiqi Zhao

Hao Jia

Xiumeng Hua

Tao An

Jiangping Song

Cardio-oncology: Shared Genetic, Metabolic, and Pharmacologic Mechanism

Truncating TTN variants (TTNtv) are the most common genetic cause of dilated cardiomyopathy (DCM), but the underlying mechanisms are incompletely understood and effective therapeutic strategies are lacking. Here we review recent data that shed new light on the functional consequences of TTNtv and how these effects may vary with mutation location.

Celine F Santiago

Inken G Huttner

Diane Fatkin

Current cardiology reports

Curr Cardiol Rep

Titin-related Cardiomyopathy: Is it a Distinct Disease?

Pharmacological treatment options for hypertrophic cardiomyopathy (HCM) are currently limited and comprise non-disease specific therapies such as β-blockers, non-dihydropyridine calcium channel blockers, and disopyramide. These agents that offer a variable degree of symptomatic relief, often suboptimal, are often limited by side-effects and fail to address the key molecular abnormalities of the disease.

Mattia Zampieri

Alessia Argirò

Alberto Marchi

Martina Berteotti

Mattia Targetti

Alessandra Fornaro

Alessia Tomberli

Pierluigi Stefàno

Niccolò Marchionni

Iacopo Olivotto

Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy.

马瓦卡门汀：一种治疗梗阻性肥厚型心肌病的新型疗法。

Advances in oncologic therapies have led to considerable improvements in prognosis and survival. However, these improvements may ultimately be diminished by the increase of cardiovascular side effects. Typically, both conventional and new antitumoral therapies may induce asymptomatic or symptomatic left ventricular dysfunction. Its development still remains a major deterrent that may compromise clinical effectiveness of cancer treatment, independently of the oncologic prognosis, having a serious impact on the patient's survival and quality of life. Hence, prevention of cardiotoxicity remains a crucial topic both for cardiologists and oncologists. Many strategies to mitigate the risk of cardiotoxicity have been developed, including cardiac function monitoring, limitation of chemotherapy doses, use of anthracycline analogues and cardioprotectants, and early detection of cardiotoxicity by biomarkers, followed by prophylactic intervention in selected high risk patients. We reviewed the currently available approaches which have been demonstrated to be effective in preventing or limiting cancer drug-induced cardiotoxicity.

Daniela Cardinale

Gina Biasillo

Carlo Maria Cipolla

Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss.

治愈癌症，拯救心脏：心脏肿瘤学不应错过的挑战。

An ever-increasing array of chemotherapeutic agents is being used in the treatment of solid organ or hematologic malignancies. The success of many of these agents has led to an increasing survival of patients with cancer. However, many of these agents, particularly anthracyclines and trastuzumab, are associated with the development of cardiotoxicity. The current standard for the evaluation of chemotherapy-associated cardiotoxicity typically involves the use of serial measurements of left ventricular (LV) function by echocardiogram (Echo) and radionuclide ventriculogram (MUGA). Unfortunately, this time-honored method offers low sensitivity to the early prediction or detection of cardiac events. Frequently, by the time cardiotoxicity is detected, significant LV dysfunction has occurred and ultimately this may not respond to standard cardioprotective treatment. Cardiac biomarkers, troponin I and B-type natriuretic peptide, may allow a more accurate and timely monitoring strategy. The current data and a summarized understanding of how to utilize cardiac biomarkers for the prevention and early detection of cardiac dysfunction during chemotherapy are presented.

Patrick L Stevens

Daniel J Lenihan

Cardiotoxicity due to Chemotherapy: the Role of Biomarkers.

化疗引起的心脏毒性：生物标志物的作用。

Abstract Purpose of the Review Successful catheter ablation of ventricular arrhythmias depends on identifying the critical tissues that sustain the arrhythmia. Increasingly, the intramural space is being recognized as an important source of idiopathic and reentrant ventricular arrhythmias, representing a common cause of ablation failure. A systematic approach to mapping and ablating these arrhythmias is key to optimize outcomes. Recent Findings Intramural ventricular arrhythmias are common in certain anatomical locations such as the left ventricular ostium or the interventricular septum. In these cases, mapping of the septal coronary veins provides an opportunity to explore the intramural compartment of the septum to perform activation mapping, entrainment and/or pace mapping. When an intramural arrhythmia is identified, ablation may require radiofrequency application from multiple sites, prolonged lesions, or special ablation techniques such as bipolar ablation or transvenous ethanol injection. Summary Identification of intramural ventricular arrhythmias depends on comprehensive mapping that should include the coronary venous system, and ablation often requires advanced techniques. This paper provides a guide on when to suspect an intramural ventricular arrhythmia in the electrophysiology laboratory and how to approach mapping and ablation in these challenging cases.

Matthew Hanson

Andres Enriquez

Fermin Garcia

Intramural Ventricular Arrhythmias: How to Crack a Hard Nut

心室肌内异位心律失常：如何破解难题

This opinion paper highlights the advancements in artificial intelligence (AI) technology for cardiovascular disease (CVD), presents best practices and transformative impacts, and addresses current concerns that must be resolved for broader adoption.

Patrícia Bota

Geerthy Thambiraj

Sandeep C Bollepalli

Antonis A Armoundas

Artificial Intelligence Algorithms in Cardiovascular Medicine: An Attainable Promise to Improve Patient Outcomes or an Inaccessible Investment?

心血管医学中的人工智能算法：改善患者预后的可实现承诺还是难以触及的投资？

Venous leg ulcers (VLUs) are one of the most common forms of chronic wounds and with nearly half the people having recurrent episodes, this significantly impacts a patient's quality of life. As such, VLU is a chronic disease that requires lifelong maintenance and awareness. A correct diagnosis of VLU is essential for management.

Jordan Blake Iceton

Alex Haro

Judy Lau

Eri Fukaya

Venous Insufficiency: Wound Management

静脉功能不全：伤口管理

Abstract Purpose of Review This review details the significant advancement in knowledge of Immune-checkpoint inhibitor (ICI) and its potential deleterious cardiac immune-related adverse effects (irAE). We explore their mechanisms on the cardiac tissue, providing guidance on risk factors, clinical presentations, diagnostic strategies along with treatment. Recent Findings Recent findings have provided insights of cardiac irAEs that exist beyond the previously well-known ICI-induced myocarditis. We have a better understanding of the wide variety of cardiac irAEs pathologies both early and late onset. Moreover, there is more data on mechanisms of cardiotoxicity and patient and therapy-related risk factors, supporting closer routine cardiac monitoring with biomarkers and imaging for prevention and early detection. Summary Diagnosing cardiac irAEs is a challenge given its broad clinical presentation. A high-level of suspicion in addition to early work-up is crucial to prevent serious cardiac events. A multi-disciplinary team including Cardiologists and Oncologists is essential for closely monitor patients’ cardiac status on ICI therapy. There is a need of updated guidelines to establish clear recommendations in patients on ICIs.

Maria T. Gamero

Avish Patel

Eugene Storozynsky

The Good (Tumor Killing) and the Bad (Cardiovascular Complications) of Immunologic Checkpoint Inhibitors

免疫检查点抑制剂的利与弊：肿瘤杀伤效果与心血管并发症

To describe the emerging role of transcatheter septal myotomy in the treatment of hypertrophic obstructive cardiomyopathy.

短名	Curr Cardiol Rep
Journal Impact	3.28
国际分区	CARDIAC & CARDIOVASCULAR SYSTEMS(Q2)
期刊索引	SCI Q2中科院 3 区

ISSN	1523-3782, 1534-3170
h-index	68
国内分区	医学(3区)医学心脏和心血管系统(3区)

涉及主题	医学内科学心脏病学生物心理学病理外科精神科放射科重症监护医学化学内分泌学生物化学疾病心力衰竭心肌梗塞
出版信息	出版商: Springer，出版周期: 12 issues per year，期刊类型: journal，开源期刊: 否
基本数据	创刊年份: 1999，原创研究文献占比: 0.00%，自引率:0.00%， Gold OA占比: 14.72%

Current Cardiology Reports

期刊引文格式

有 1 位以上作者的期刊

有 2 位作者的期刊

有 3 位作者的期刊

有 5 位以上作者的期刊

书籍引用格式

学位论文引用格式

网页引用格式

专利引用格式

手工熬夜修改参考文献？研飞自动匹配期刊，一键轻松成稿，支持 Word/WPS

投稿经验分享